Nuclear survivin as a biomarker for non-small-cell lung cancer

被引：0
|
作者：
B Lu
A Gonzalez
P P Massion
Y Shyr
B Shaktour
D P Carbone
D E Hallahan
机构：
[1] Vanderbilt Ingram,Department of Radiation Oncology
[2] Cancer Center,Department of Pathology
[3] Vanderbilt University School of Medicine,Department of Medicine
[4] Vanderbilt Ingram,Department of Preventive Medicine
[5] Cancer Center,undefined
[6] Vanderbilt University School of Medicine,undefined
[7] Vanderbilt Ingram,undefined
[8] Cancer Center,undefined
[9] Vanderbilt University School of Medicine,undefined
[10] Vanderbilt Ingram,undefined
[11] Cancer Center,undefined
[12] Vanderbilt University School of Medicine,undefined
来源：
British Journal of Cancer | 2004年 / 91卷
关键词：
survivin; lung cancer; nucleus; tissue array; mitosis; apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Survivin inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localisation of survivin predicts survival of 48 patients with resected non-small-cell lung cancer (NSCLC). Patients with nuclear staining of survivin had significantly worse survival (relative risk: 3.9, P=0.02). Therefore, survivin may be a biomarker for NSCLC.
引用
收藏
页码：537 / 540
页数：3
相关论文
共 50 条
  • [31] XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer
    Yi Yuli
    Sun Zhe
    Wang Xia
    Li Siqing
    Wu Zhenxuan
    Zhu Yu-hua
    Sun Bing
    Cui Jun-wei
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2013, 29 (03) : 762 - 767
  • [32] TIME for biomarker-driven immunotherapy in non-small-cell lung cancer patients
    Karachaliou, Niki
    Rosell, Rafael
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 127 - 130
  • [33] Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea
    Jung, Young Ju
    Katilius, Evaldas
    Ostroff, Rachel M.
    Kim, Youndong
    Seok, Minkyoung
    Lee, Sujin
    Jang, Seongsoo
    Kim, Woo Sung
    Choi, Chang-Min
    CLINICAL LUNG CANCER, 2017, 18 (02) : E99 - E107
  • [34] Avelumab in non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2018, 19 (11): : 1423 - 1424
  • [35] Radiochemotherapy in non-small-cell lung cancer
    Swartman, B.
    Hausmanns, J.
    Zwicker, F.
    Thomas, M.
    Herfarth, K.
    Heussel, C. P.
    MEDIZINISCHE KLINIK, 2011, 106 (03) : 212 - 217
  • [36] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [37] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
  • [38] Immunohistochemical Analysis Of Biomarker Expression And Chemotherapeutic Efficacy In Non-Small-Cell Lung Cancer
    Okimoto, T.
    Sutani, A.
    Tsubata, Y.
    Tanino, R.
    Hotta, T.
    Koba, N.
    Hamaguchi, M.
    Miura, K.
    Hamaguchi, S.
    Ohe, M.
    Awaya, Y.
    Takeyama, H.
    Isobe, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [39] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [40] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    PET CLINICS, 2018, 13 (01) : 1 - +
12345